Zoetis Inc. shares dropped about 21.5% on May 7, 2026, after the company sharply cut its full-year 2026 revenue guidance to $9.68-$9.96 billion, down from a previously stated 3%-5% organic growth forecast. The revision came as internal data revealed weakening U.S. pet-care demand and increased competition, particularly a looming generic threat to its top dermatology drug. This sudden guidance cut surprised investors who were not aware of these internal challenges, leading to significant losses. Legal firm Levi & Korsinsky is investigating potential securities law violations related to possibly misleading statements made by Zoetis about its revenue outlook and market conditions.
